# Okogen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/okogen

- Industry: Pharmaceuticals
- Headquarters: Plano, US
- Website: www.okogen.com
- Total disclosed funding: $6.2M
- Latest round: Series A (Dec 22, 2017)
- Investors on record: 1

## About

Based in the US, Okogen, Inc. is a clinical-stage ophthalmic pharmaceutical company focused on developing innovative treatments for acute infectious conjunctivitis, addressing significant unmet needs in eye care.Okogen, Inc. was founded in 2015 in Plano, US, as a clinical stage company specializing in ophthalmic pharmaceuticals. The firm has completed 2 funding deals, with the most recent being a Series B round in November 2024, raising USD 2.451 mn. The current company valuation stands at USD 4.270 mn. The company is led by CEO Brian Strem and Joshua Moriarty.Okogen, Inc. is primarily focused on developing treatments for acute infectious conjunctivitis, particularly bacterial and viral forms. Their lead product is currently in Phase 2B clinical trials, targeting the annual USD 4.2 billion conjunctivitis market, which is expected to expand significantly by 2031. The company aims to address the lack of approved therapies for adenoviral conjunctivitis, serving healthcare providers, clinics, and hospitals across the US and Australia.Okogen, Inc. operates a revenue model built around the development and potential commercialization of its pharmaceutical products. Revenue is expected to be generated through partnerships with healthcare institutions and direct sales to healthcare providers as the firm progresses through clinical trials. The model focuses on a market where 85% of treatments for conjunctivitis rely on antibiotics, positioning Okogen strategically as it introduces its innovative solutions.In November 2024, Okogen, Inc. raised USD 2.45 million in Series B funding, which will be utilized to support its AI-driven home application platform and advance its Phase 2B clinical program for acute infectious conjunctivitis. The firm aims to launch its new products targeting this underserved market while expanding into new geographical regions, with specific plans to penetrate both the US and Australian healthcare markets by 2031.

## Funding rounds

- Series A, Dec 22, 2017, $6.2M — Brandon Capital Partners

## Investors

- Brandon Capital Partners (https://capitalatlas.ai/funds/brandon-capital-partners) — Series A